Virax Biolabs Group Limited Ordinary Shares (VRAX) Short Interest, Short Squeeze & Borrow Rates LIVE

BW Analyst read

Virax Biolabs Group Limited Ordinary Shares (NASDAQ: VRAX) had 23,357 shares sold short as of the August 14, 2026 settlement date, as reported by FINRA. That is 4.4% of the company's free float and a days-to-cover ratio of 1.00.

Virax Biolabs Group Limited Ordinary Shares (NASDAQ: VRAX) is a healthcare company whose short-side positioning we track across four independent reporting systems: exchange short interest settled twice a month, FINRA off-exchange short volume published every trading day, SEC fails to deliver that arrive about two weeks in arrears, and securities-lending terms that move intraday. Each carries its own as-of date, so the sections below are read alongside one another rather than as a single snapshot.

Borrowing VRAX indicates around 348.1% annualised, a level that reflects tight lending supply at the reporting facility rather than a market-wide rate. As of the August 14, 2026 settlement, 23,357 VRAX shares were reported short, equal to 4.4% of its free float. FINRA reported a 25.8% decrease at the most recent settlement.

The measured drivers disagree: a borrow fee near 348.1% sits toward the stretched end, while short interest at 4.4% of float and days to cover at 1.00 do not. A mixed reading like this says more than any single figure taken alone.

Our squeeze score reads 22 out of 100, higher than 28% of the 5,108 US stocks we currently score. It shares that score with 209 other stocks, so this is a band rather than a precise placing.

One thing affects how this history should be read — a stock split restated the share count at the June 30, 2026 settlement, so totals before and after that date are counted in different units and are not directly comparable.

Reported short interest for VRAX at each date, shown with days to cover and short interest as a percent of float. Short interest updates twice a month; the percentages are recomputed as float changes.

How many VRAX shares were sold short off exchange each day, summed across the reporting venues we track. It includes market maker hedging and other routine activity, so a high reading is normal and is not the same as outstanding short interest.

The same off-exchange volume above, split across the FINRA trade reporting facilities that publish it. These are reporting venues, not exchanges — FINRA publishes off-exchange activity only, so this is not a full market count and the rows are not summed here. The consolidated total in the section above is the authoritative figure.

VRAX shares that did not settle on time, reported by the SEC. Each figure is a running balance on a given date rather than a daily tally, and it is not added up across dates. Fails happen for many ordinary reasons and are not on their own a sign of anything improper.

The annualized rate a short seller pays to borrow VRAX. The latest reading is 348.13%. A high or rising fee means shares are getting harder and more expensive to short, which is one of the conditions that can feed a squeeze.